Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cruz-Fernandez, J.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cruz-Fernandez, J.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Antiplatelet drugs in the treatment of acute coronary syndromes: Focus on cyclooxygenase inhibitors

J.M. Cruz-Fernandez1

Department of Medicine (Cardiology), School of Medicine, University of Seville and Cardiology Service, Hospital Universitario Virgen de Macarena, 41071 Seville, Spain

1 Correspondence: JosÉ M. Cruz-Fernández, Avda. Repúbica Argentina 15, 5-A, 41011 Seville, Spain.
jmcruz{at}hmv.sas.cica.es

Abstract

Despite its widespread use and documented efficacy in the treatment of acute coronary syndromes, aspirin has some limitations and the search for more effective and safer alternatives continues. This article analyses some current aspects of the treatment of these syndromes with the cyclooxygenase inhibitor triflusal.

Triflusal inhibits platelet cyclooxygenase activity but does not interfere significantly with endothelial synthesis of prostacyclin via the cyclooxygen ase-2 pathway. This drug also increases nitric oxide synthesis by neutrophils, and decreases the activity of nuclear transcription factor NF-B more than aspirin does. Moreover, triflusal inactivates intraplatelet phosphodiesterase and potentiates the antiaggregant effect of cAMP and cGMP, since it interferes with the degradation of these compounds. These pharmacological differences make triflusal potentially more effective and safer than aspirin.

For unstable angina or non-Q-wave myocardial infarction, triflusal is as effective as aspirin. In a multicentre study of more than 2000 patients with acute myocardial infarction, triflusal was as effective as aspirin, and had a better safety profile, significantly decreasing (> 60%) the incidence of cerebrovascular accidents. The patients likely to benefit most from treatment with triflusal were those receiving fibrinolytic treatment, patients older than 65 years, and those receiving concomitant treatment with angiotensin-converting enzyme inhibitors.

Triflusal is currently a valid alternative to aspirin for unstable angina, and for acute myocardial infarction it is the only alternative drug shown to be as effective as aspirin but safer.

Key Words: Acute coronary syndromes • antiplatelet agents • aspirin • cyclooxygenase inhibitors • triflusal

References

  1. Knight CJ. New insights into the pathophysiology of acute coronary occlusion. Eur Heart J Suppl. 1999;1(Suppl F):F3–F6
  2. Kaski JC. Local cytokine production and acute coronary events. Int J Cardiol. 2000;73:79–81[CrossRef][Web of Science][Medline]
  3. Badimón JJ, Lettino M, Toschi V, et al. Local inhibitionn of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effect of tissue factor pathway inhibitor on plaque: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:17980–17987
  4. Rupprecht HJ. Adenosine diphosphate receptor antagonists: from pharmacology to clinical practice. Eur Heart J. 2000;(Suppl E):E1–E5m
  5. Task Force of the European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 2000;21:1406–1432[Free Full Text]
  6. Antiplatelet Trialists' Collaboration. Collaborative overview of ramdomised trials of antiplatelet therapy. is prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106[Abstract/Free Full Text]
  7. Lewis HD, Davis JW, Archibald DJ, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administrative Group Study. N Engl J Med. 1983;309:396–403[Abstract]
  8. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830[CrossRef][Web of Science][Medline]
  9. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med. 1985;313:1369–1375[Abstract]
  10. Theroux P, Quimet H, McCans J, et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111[Abstract]
  11. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet. 1988;ii:349–360
  12. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–1294[Free Full Text]
  13. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival. A cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425[Abstract/Free Full Text]
  14. Vane JR. Towards a better aspirin. Nature (London). 1994;367:215–216[CrossRef][Medline]
  15. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000;160:913–920[Abstract/Free Full Text]
  16. Gutthann SP. Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med. 1996;156:2433–2439[Abstract/Free Full Text]
  17. Vane JR, Botting RM. Mechanisms of action of aspirin-like drugs. Sem Arthritis Rheum. 1997;26:2–10[CrossRef][Web of Science][Medline]
  18. Van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors. Pharmacology, clinical effects and therpeutic potential. Exp Opin Invest Drugs. 1997;6:609–614[CrossRef]
  19. Cohn SM, Schloemann S, Tessner T, et al. Crypt stem cell survival in the mouse intestinal epithelium is regulated by Prostaglandins synthesized through cyclooxygenase-1. J Clin Invest. 1997;99:1367–1379[Web of Science][Medline]
  20. Langenbach R, Morham SG, Tirano HE, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacine-induced gastric ulceration. Cell. 1995;83:483–492[CrossRef][Web of Science][Medline]
  21. McAdam BE, Catella-Lawson F, Mardini NA, et al. Systemic biosynthesis of prostacyclin by cyclooxygense (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999. p. 272–277
  22. Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol. 1998;355:211–217[CrossRef][Web of Science][Medline]
  23. Willoughby DA, Moore AR, Colvill-Nash PR. COX-1, COX-2 and COX-3 and the treatment of chronic inflammatory disease. Lancet. 2000;355:646–648[CrossRef][Web of Science][Medline]
  24. Hawkay CJ. COX-2 inhibitors. Lancet. 1999;353:307–314[CrossRef][Web of Science][Medline]
  25. Sanchez de Miguel L, Montón M, Arriero MM, et al. Effect of triflusal on human platelet aggregation and secretion: role of nitric oxide. Rev Esp Cardiol. 2000;53:205–211[Web of Science][Medline]
  26. Carcia-Rafanell J, Ramis J, Gomez L, et al. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch Int Pharmacodyn Ther. 1986;284:155–165[Web of Science][Medline]
  27. Bayón Y, Alonso A, Sanchez Crespo M. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor KB activation. Br J Pharmacol. 1999;126:1359–1366[CrossRef][Web of Science][Medline]
  28. Laufer S, Striegel HG, Neher C, et al. Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors. Arch Pharm (Weinheim). 1997;330:307–312[CrossRef][Medline]
  29. De la Cruz JP, Pavia I, García-Arnés J, et al. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur J Haematol. 1988;40:232–236[Web of Science][Medline]
  30. Bombardier C, Laie L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxene in patients with rheumatoid arthritis. N Engl J Med. 2000;346:1520–1528
  31. Cruz-Fernandez JIM, Lopez V, Marfil F, et al. Managing acute myocardial infarction: clinical implications of the TIM study. Eur Heart J Suppl. 1999;1(Suppl F):F12–F18
  32. McNeely W, Goa KL. Triflusal. Drugs. 1998;55:823–833[CrossRef][Web of Science][Medline]
  33. Bayés de Luna A. May aspirin be replaced in the treatment of myocardial infarction? Eur Heart J. 2000;21:430–432[Free Full Text]
  34. Guiteras P, Altimiras J, Aris A, et al. Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-bind, placebo-controlled trial. Eur Heart J. 1989;10:159–167[Abstract/Free Full Text]
  35. Masotti M, Tura A, Crexels C, et al. Antiplatelet agents and their effect on complications during or soon after percutaneous transluminal coronary angioplasty. J Int Med Res. 1991;19:414–418[Web of Science][Medline]
  36. Plaza L, López-Bescós L, Martín-Jadraque L, et al. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicentre trial. Grupo de Estudio del Triflusal en la Angina Inestable. Cardiology. 1993;82:388–398[Web of Science][Medline]
  37. Cruz-Fernandez JM, López-Bescós L, Garcia-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J. 2000;21:457–465[Abstract/Free Full Text]
  38. López Bescós L, Cabades A, Castro-Beiras A, et al. Incidence of vascular stroke in patients with acute myocardial infarction receiving fibrinolytic treatment. Eur Heart J Suppl. 2000;1(Suppl F):F19–F23
  39. Garcia-Dorado D, Velasco J, Virgós A, et al. Interaction between antiplatelet agents and ACE inhibitors in patients with acute myocardial infarction. Eur Heart J Suppl. 2000;1(Suppl F):F24–F28

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cruz-Fernandez, J.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cruz-Fernandez, J.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?